ArticleInfection & chemotherapy2026
Prevalence and Risk Factors of Latent Tuberculosis Infection among People Living with HIV in Mongolia.
Article in Infection & chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundTuberculosis (TB) remains the leading cause of death among people living with human immunodeficiency virus (PLHIV). Latent tuberculosis infection (LTBI) poses a serious challenge because immune suppression substantially increases the risk of progression to active disease. In Mongolia, where TB incidence is high, little is known about LTBI prevalence and risk factors among PLHIV. This study aimed to estimate the prevalence of LTBI and identify risk factors for LTBI in Mongolia. MATERIALS AND
methodsA retrospective cohort study was conducted using secondary data from the AIDS/STI Surveillance and Research Department of the National Centre for Communicable Diseases between September 2023 and January 2024. A total of 196 PLHIV without active TB were screened using the QuantiFERON-TB Gold Plus test. Sociodemographic and clinical variables were analyzed with chi-square tests and multivariable logistic regression.
resultsThe prevalence of LTBI was 39.3% (77/196). Interruption of antiretroviral therapy was significantly associated with (odds ratio, 27.7; 95% confidence interval, 3.04-252.2). The history of TB contact was also associated with high risk (
conclusionThese findings indicate that LTBI prevalence among PLHIV in Mongolia is high, comparable to other high-burden settings. Ensuring continuous ART use, implementing systematic LTBI screening, and expanding preventive therapy are critical to reduce progression to active TB and to strengthen TB/HIV control efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.